We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LIQT:NASDAQLiqTech International, Inc. Analysis

Data as of 2026-06-13 - not real-time

$0.87

Latest Price

8/10Risk

Risk Level: High

Executive Summary

LiqTech International (LIQT) is trading at $0.87, barely above the calculated support of $0.74 and well below its 20‑day SMA of $1.32, indicating a strong bearish price trend. Technical indicators reinforce this view: RSI is at 29.9 (oversold), MACD histogram is negative, and the MACD signal is bearish, yet volume is trending upward, suggesting some buying interest may be forming. The stock’s beta of 1.19 and a 30‑day volatility of 162% point to pronounced price swings, while the max drawdown of nearly 73% underscores historical downside risk. Fundamentally, the company posted a 10% YoY revenue decline to $16 M, with gross margins under 10% and operating margins at –55%, resulting in a net loss of $0.92 per share and negative free cash flow. Its balance sheet is strained, featuring a debt‑to‑equity ratio of 170% and cash of only $2.7 M against $12.9 M of debt, though the recent $20 M public offering at $1.00 per share adds some liquidity cushion. Recent news highlights a 32% sequential revenue increase and entry into the U.S. market, offering a potential catalyst, but earnings missed expectations and the company remains unprofitable, making the outlook highly contingent on a successful turnaround.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 5/10

Key Factors

  • Oversold RSI and proximity to support level
  • Increasing trading volume indicating potential accumulation
  • Potential short‑term bounce despite weak fundamentals

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Recent $20 M capital raise providing liquidity
  • Sequential revenue growth and U.S. market entry
  • Continued negative earnings and high leverage

Long Term

> 3 years
Cautious
Model confidence: 3/10

Key Factors

  • Sustained operating losses and negative cash flow
  • Elevated debt‑to‑equity ratio limiting financial flexibility
  • High volatility and historical drawdowns reducing risk‑adjusted returns

Key Metrics & Analysis

Financial Health

Revenue Growth-10.40%
Profit Margin-55.45%
P/E Ratio-1.2
ROE-79.31%
ROA-18.26%
Debt/Equity170.75
P/B Ratio1.1
Op. Cash Flow$-6752461
Free Cash Flow$-3659042
Industry P/E30.6

Technical Analysis

TrendBearish
RSI29.9
Support$0.74
Resistance$2.16
MA 20$1.32
MA 50$1.75
MA 200$1.93
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Target Price$4.40
Upside/Downside405.75%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.19
Volatility162.35%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.